Description
ADCC-Enhanced anti-IL18 (2C10) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Crohn's Disease; Diabetes Type 2; Ulcerative Colitis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL18 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Background
The protein encoded by this gene is a proinflammatory cytokine that augments natural killer cell activity in spleen cells, and stimulates interferon gamma production in T-helper type I cells. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Alternative Names
IL18; interleukin 18; IGIF; IL-18; IL-1g; IL1F4; interleukin-18; IL-1 gamma; iboctadekin; interleukin-1 gamma; IFN-gamma-inducing factor; interleukin 18 (interferon-gamma-inducing factor)
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IL18 include Adult-Onset Still's Disease and Shigellosis.
Related Pathways
Its related pathways are Cellular roles of Anthrax toxin and Tuberculosis.
Function
A pro-inflammatory cytokine, mainly involved in polarizing T-helper 1 (Th1) cells and natural killer (NK) cell immune response (possibly). Combine with IL18R1 and IL18RAP to form a signal triad, activate nf-kpa-b, and trigger the synthesis of inflammatory mediators. Cooperating with IL12/Interleukin-12 to induce T-helper 1 (Th1) cells and natural killer cells (NK) to synthesize IFNG (Probable).
Field of research
Cancer antibody; Immune System antibody; Metabolism antibody
Post-translational modifications
The pro-IL-18 precursor is processed by CASP1 or CASP4 to yield the active form.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
GSK1070806 is a humanised IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18). GSK1070806 was generally well tolerated. The most common AEs were nasopharyngitis and headache, arising as frequently in the placebo as in the active drug groups; most AEs were mild to moderate and unrelated to dose level. There were no allergic, delayed-type hypersensitivity, or infusion-related reactions and the incidence of immunogenicity was low.
Antibody Indication
Crohn's Disease; Diabetes Type 2; Ulcerative Colitis
